Impact of COVID-19 Vaccination in Thailand: Averted Deaths and Severe Infections Across Age Groups DOI Creative Commons
Chaiwat Wilasang, Pikkanet Suttirat, Dhammika Leshan Wannigama

и другие.

Tropical Medicine and Infectious Disease, Год журнала: 2024, Номер 9(12), С. 286 - 286

Опубликована: Ноя. 22, 2024

The COVID-19 pandemic has underscored the pivotal role of vaccines in mitigating devastating impact virus. In Thailand, vaccination campaign against SARS-CoV-2 began on 28 February 2021, initially prioritizing healthcare professionals before expanding into a nationwide effort 7 June 2021. This study employs mathematical model transmission with to analyze Thailand's program from 1 March 2021 31 December 2022. We specifically assess potential loss lives and occurrence severe infections across various age groups hypothetical scenario where were not administered. By fitting our officially reported death data, analysis reveals that efforts prevented total 300,234 deaths (95% confidence interval: 295,938-304,349) averted 1.60 million 1.54-1.65 million). Notably, elderly population over 80 years old benefited most vaccination, an estimated 84,518 saved, constituting 4.28% this group. Furthermore, individuals aged between 70 74 experienced highest reduction infections, potentially preventing 8.35% bracket developing COVID-19.

Язык: Английский

Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial DOI Creative Commons
Dhammika Leshan Wannigama, Cameron Hurst, Phatthranit Phattharapornjaroen

и другие.

EClinicalMedicine, Год журнала: 2024, Номер 70, С. 102517 - 102517

Опубликована: Март 14, 2024

Repurposed drugs with host-directed antiviral and immunomodulatory properties have shown promise in the treatment of COVID-19, but few trials studied combinations these agents. The aim this trial was to assess effectiveness affordable, widely available, repurposed used combination for which may be particularly relevant low-resource countries.

Язык: Английский

Процитировано

9

Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series DOI Creative Commons

Shuichi Abe,

Dhammika Leshan Wannigama, Yu Suzuki

и другие.

New Microbes and New Infections, Год журнала: 2024, Номер 62, С. 101522 - 101522

Опубликована: Окт. 30, 2024

Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.

Язык: Английский

Процитировано

2

Comparative Analysis of RT-PCR, RT-LAMP, and Antigen Testing Strategies for Effective COVID-19 Outbreak Control: A Modeling Study DOI Creative Commons

Tanakorn Chantanasaro,

Chayanin Sararat, Noppamas Yolai

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Июль 15, 2024

Abstract The COVID-19 pandemic has highlighted the crucial role of testing in mitigating disease transmission. This study comprehensively evaluates effectiveness and cost-efficiency various strategies, including daily screening, symptom-based testing, contact-based using assays such as RT-PCR, RT-LAMP, antigen tests. Employing stochastic modeling on a contact network, we assessed impact these strategies outbreak control, case study. Our findings demonstrate that particularly with RT-PCR significantly reduces transmission risks but incurs higher costs. In contrast, offers more cost-effective alternative, albeit lower efficacy outbreaks. Notably, turnaround time emerges critical factor than assay sensitivity containing Moreover, combining tracing further probability scale. To provide comprehensive analysis, also explored application scenarios where portion population acquired immunity. results suggest all symptomatic individuals is most effective cost-efficient approach later stages an epidemic. These valuable insights for optimizing to tackle current future infectious outbreaks effectively efficiently. By adapting based stage epidemic, immunity, available resources, public health authorities can design targeted interventions protect communities while managing limited resources.

Язык: Английский

Процитировано

0

Modeling the Risk of Airborne Transmission of Respiratory Viruses in Microgravity DOI Creative Commons
Chayanin Sararat, Natnicha Jiravejchakul, Kawin Nawattanapaiboon

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Сен. 6, 2024

Abstract Airborne transmission is the most efficient and widespread route of viral spread, posing a significant challenge in controlling major infectious diseases such as COVID-19 influenza. In microgravity environment, International Space Station (ISS), this mode requires heightened vigilance preventive measures due to prolonged suspension virus-laden particles, which increases risk infection. Using COVID Risk Assessment (CARA) tool, we assess airborne respiratory viruses by simulating emission, dispersion, inhalation particles. Our findings show that unique conditions allow these particles remain for significantly longer periods compared Earth, leading 286-fold increase virus concentration air, resulting nearly twice probability infection susceptible host. We also evaluated effectiveness measures, found facemasks can reduce up 23% while continuous HEPA filtration at five air changes per hour proves crucial managing quality minimizing risks reducing 99.79%. However, when simulated accounting spaceflight-induced immune suppression, increased 12% condition load infected host 8-fold absence protective measures. Although help mitigate risk, their diminishes carrying high. Enhancing immunity through vaccination or other interventions vital, potentially 14.17% combined with filtration. These highlight need robust mitigation strategies safeguard health astronauts against pathogens during future space missions.

Язык: Английский

Процитировано

0

Impact of COVID-19 Vaccination in Thailand: Averted Deaths and Severe Infections Across Age Groups DOI Creative Commons
Chaiwat Wilasang, Pikkanet Suttirat, Dhammika Leshan Wannigama

и другие.

Tropical Medicine and Infectious Disease, Год журнала: 2024, Номер 9(12), С. 286 - 286

Опубликована: Ноя. 22, 2024

The COVID-19 pandemic has underscored the pivotal role of vaccines in mitigating devastating impact virus. In Thailand, vaccination campaign against SARS-CoV-2 began on 28 February 2021, initially prioritizing healthcare professionals before expanding into a nationwide effort 7 June 2021. This study employs mathematical model transmission with to analyze Thailand's program from 1 March 2021 31 December 2022. We specifically assess potential loss lives and occurrence severe infections across various age groups hypothetical scenario where were not administered. By fitting our officially reported death data, analysis reveals that efforts prevented total 300,234 deaths (95% confidence interval: 295,938-304,349) averted 1.60 million 1.54-1.65 million). Notably, elderly population over 80 years old benefited most vaccination, an estimated 84,518 saved, constituting 4.28% this group. Furthermore, individuals aged between 70 74 experienced highest reduction infections, potentially preventing 8.35% bracket developing COVID-19.

Язык: Английский

Процитировано

0